Concord Drugs Ratios

Concord Drugs Ltd Ratios

The Concord Drugs Ltd Ratios page provides a complete fundamental analysis of Concord Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Concord Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Concord Drugs Ltd (NSE: , BSE: 538965) is currently trading at ₹76.77, with a market capitalization of ₹0. As a major player in the Health technology sector and Pharmaceuticals: major industry, Concord Drugs Ltd remains a key stock for fundamental analysis using Concord Drugs Ltd Ratios.

Concord Drugs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Concord Drugs Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Concord Drugs Ltd Ratios.

Historically, the Concord Drugs Ltd P/E ratio has shown strong fluctuations:

The decline in Concord Drugs Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Concord Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Concord Drugs Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Concord Drugs Ltd P/S ratio currently stands at 0, an important part of Concord Drugs Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Concord Drugs Ltd P/S ratio indicates cautious market sentiment.

Concord Drugs Ltd Price to Cash Flow Ratio (P/CF)

The Concord Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Concord Drugs Ltd Price to Cash Flow Ratio:

The declining Concord Drugs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Concord Drugs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Concord Drugs Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Concord Drugs Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Concord Drugs Ltd EV/EBITDA ratio is currently 0, a key metric in Concord Drugs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Concord Drugs Ltd EV/EBITDA indicates balanced valuation.

Concord Drugs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Concord Drugs Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Concord Drugs Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Concord Drugs Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Concord Drugs Ltd Ratios Analysis Summary

The Concord Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Concord Drugs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Concord Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.